Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Infosys Limited (INFY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Infosys Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Infosys Limited trades at $11.19 (market cap $45.83B). The key difference: Alnylam Pharmaceuticals, Inc. and Infosys Limited are close in size by market cap, and Infosys Limited pays a 4.79% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | INFY | |
|---|---|---|
Market Cap | $39.89B | $45.83B |
Sector | Health | Technology |
52-Week High | $491.22 | $20.22 |
52-Week Low | $278.09 | $10.49 |
Enterprise Value | $38.15B | $43.05B |
Dividend Yield | — | 4.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
INFY trades at $10.94, down 1.71% for the day, with technical indicators showing a bearish trend. The company maintains strong profitability with 16.44% net margins and 31.57% ROE, though recent earnings show mixed results with one miss and two beats. Recent news highlights INFY's aggressive AI partnerships across healthcare, banking, and media sectors, positioning the company for digital transformation leadership.
The stock presents a valuation opportunity with P/E of 13.68 below industry averages, supported by analyst consensus target of $12.14 (11% upside). Key risks include competitive pressures in IT services and potential margin compression from AI investments. Current institutional sentiment leans neutral with 52.5% hold ratings amid transitional business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
